3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Completed
9
Recruiting
3
Withdrawn
1
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
2
Breast
1
Conditions
Pancreatic Neoplasms
56
Biliary Tract Neoplasms
24
Cholangiocarcinoma
23
Nasopharyngeal Carcinoma
22
Carcinoma, Non-Small-Cell Lung
22
Urinary Bladder Neoplasms
18
Breast Neoplasms
18
Neoplasm Metastasis
17
Lung Neoplasms
14
Lymphoma, Large B-Cell, Diffuse
13
Colorectal Neoplasms
12
Carcinoma, Transitional Cell
12
Recurrence
9
Non-Muscle Invasive Bladder Neoplasms
9
Sarcoma
8
Ovarian Neoplasms
8
Triple Negative Breast Neoplasms
7
Neoplasms
7
Gallbladder Neoplasms
7
Hodgkin Disease
6
Nasopharyngeal Neoplasms
5
Bile Duct Neoplasms
5
Adenocarcinoma
5
Uterine Cervical Neoplasms
4
Locally Advanced Pancreatic Cancer
4
Endometrial Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Adenocarcinoma
3
Osteosarcoma
3
Lymphoma, T-Cell, Peripheral
3
Interventions
pembrolizumab
19
Paclitaxel
13
Carboplatin
10
Pemetrexed
4
Cisplatin
4
patritumab deruxtecan
3
Gemcitabine
3
Docetaxel
3
Capecitabine
3
Albumin-Bound Paclitaxel
3
Histamine H2 Antagonists
2
Histamine Antagonists
2
Dexamethasone
2
Acetaminophen
2
130-nm albumin-bound paclitaxel
2
trastuzumab deruxtecan
1
osimertinib
1
olaparib
1
liposomal doxorubicin
1
lenvatinib
1
enzalutamide
1
cemiplimab
1
Vascular Endothelial Growth Factor A
1
Serotonin 5-HT3 Receptor Antagonists
1
Ramucirumab
1
Oxaliplatin
1
Neurokinin-1 Receptor Antagonists
1
Neoadjuvant Therapy
1
Levoleucovorin
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Gemcitabine
×
Clear all
NCT06788912
2026-05-26
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled
NCT06841354
2026-05-22
TroFuse-011
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,000 enrolled
NCT06623422
2026-05-15
INTerpath-009
Merck Sharp & Dohme LLC
Phase 3
Recruiting
680 enrolled